Journal
NEUROLOGY
Volume 75, Issue 12, Pages 1062-1069Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181f39d0e
Keywords
-
Categories
Funding
- Merck Serono
- Lundbeck Inc.
- Novartis
- GE Healthcare
- GlaxoSmithKline
- Solvay Pharmaceuticals, Inc
- Parkinson's Disease Society
- Patrick Berthoud Trust
- Boehringer Ingelheim
- ACADIA Pharmaceuticals
- Osmotica Pharmaceutical Corp.
- BrainCells Inc.
- Sanofi-Aventis
- Johnson Johnson
- Solvay Pharmaceuticals, Inc.
- NIH [NIMH K23 MH067894, NINDS P50 NS053488-01, NIA RO1AG031348, NINDS R01NS065087, NS36630, 1UL1 RR024156-01, PO412196-G]
- Michael J. Fox Foundation for Parkinson's Research
- University of Pennsylvania
- Amarin Corporation
- Boehringer Ingelheim NeuroSearch
- Parkinson Disease Foundation
- Huntington's Disease Society of America
- Parkinson Study Group
- Instituto de Salud Carlos III, Spain
- Wellcome Trust
- NIHR Health Technology Assessment Programme
- Michael J Fox Foundation
- UCB
- MDS Nordion
- Orion Corporation
- Brain Research Trust
- Parkinson's Appeal
- Western Norway Health Trust
- Norwegian Research Counsel
- Norwegian Parkinson's disease Association
- Neuroscience at a Glance (Blackwell Publishing)
- UK Medical Research Council
- NIHR
- Parkinson Hastalydy (Gunes Tip Kitapevi)
- Dementia in Parkinson's Disease (Oxford University Press)
- Eli Lilly and Company
- MRC [G0800784] Funding Source: UKRI
- Medical Research Council [G0800784, G0800784B] Funding Source: researchfish
Ask authors/readers for more resources
Background: In studies of mild cognitive impairment (MCI) in Parkinson disease (PD), patients without dementia have reported variable prevalences and profiles of MCI, likely to be due to methodologic differences between the studies. Objective: The objective of this study was to determine frequency and the profile of MCI in a large, multicenter cohort of well-defined patients with PD using a standardized analytic method and a common definition of MCI. Methods: A total of 1,346 patients with PD from 8 different cohorts were included. Standardized analysis of verbal memory, visuospatial, and attentional/executive abilities was performed. Subjects were classified as having MCI if their age-and education-corrected z score on one or more cognitive domains was at least 1.5 standard deviations below the mean of either control subjects or normative data. Results: A total of 25.8% of subjects (95% confidence interval [CI] 23.5-28.2) were classified as having MCI. Memory impairment was most common (13.3%; 11.6-15.3), followed by visuospatial (11.0%; 9.4-13.0) and attention/executive ability impairment (10.1%; 8.6-11.9). Regarding cognitive profiles, 11.3% (9.7-13.1) were classified as nonamnestic single-domain MCI, 8.9% (7.0-9.9) as amnestic single-domain, 4.8% (3.8-6.1) as amnestic multiple-domain, and 1.3% (0.9-2.1) as nonamnestic multiple-domain MCI. Having MCI was associated with older age at assessment and at disease onset, male gender, depression, more severe motor symptoms, and advanced disease stage. Conclusions: MCI is common in patients with PD without dementia, affecting a range of cognitive domains, including memory, visual-spatial, and attention/executive abilities. Future studies of patients with PD with MCI need to determine risk factors for ongoing cognitive decline and assess interventions at a predementia stage. Neurology (R) 2010;75:1062-1069
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available